deltatrials
Completed PHASE1 NCT00909831

Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

A Phase I Trial of Hydroxychloroquine in Combination With Temsirolimus in Patients With Refractory Solid Tumors

Sponsor: Abramson Cancer Center at Penn Medicine

Conditions Unspecified Adult Solid Tumor, Protocol Specific
Interventions autophagy inhibition therapy electron microscopy high performance liquid chromatography hydroxychloroquine immunologic technique laboratory biomarker analysis mass spectrometry pharmacological study temsirolimus
Updated 8 times since 2017 Last updated: Apr 12, 2019 Started: Oct 31, 2008 Primary completion: May 31, 2012 Completion: Nov 30, 2013

This PHASE1 trial investigates Unspecified Adult Solid Tumor, Protocol Specific and is currently completed. Abramson Cancer Center at Penn Medicine leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. May 2023 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — May 2023 [monthly]

    Completed PHASE1

  5. May 2019 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Unknown Status → Completed

▶ Show 3 earlier versions

  1. Jun 2018 — May 2019 [monthly]

    Unknown Status PHASE1

  2. Mar 2018 — Jun 2018 [monthly]

    Unknown Status PHASE1

    Status: Active Not Recruiting → Unknown Status

  3. Jan 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center at Penn Medicine
  • National Cancer Institute (NCI)
Data source: Abramson Cancer Center at Penn Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Philadelphia, United States